


FT709

Cat. No.:	HY-145967		
CAS No.:	2413991-74-7		
Molecular Formula:	C ₂₃ H ₂₂ N ₄ O ₇ S		
Molecular Weight:	498.51		
Target:	Deubiquitinase		
Pathway:	Cell Cycle/DNA Damage		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (200.60 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.0060 mL	10.0299 mL	20.0598 mL
	5 mM	0.4012 mL	2.0060 mL	4.0120 mL
	10 mM	0.2006 mL	1.0030 mL	2.0060 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: 2.5 mg/mL (5.01 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (5.01 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: 2.5 mg/mL (5.01 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

FT709 is a potent and selective USP9X inhibitor, an IC₅₀ of 82 nM. USP9X has been linked with centrosome function, chromosome alignment during mitosis, EGF receptor degradation, chemo-sensitization, and circadian rhythms^[1].

In Vitro

FT709 (10 μM, 24 h) decreases levels of ZNF598 (ubiquitin E3 ligase) and the centrosomal protein CEP55 in HCT116 cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Clancy A, et, al. The deubiquitylase USP9X controls ribosomal stalling. J Cell Biol. 2021 Mar 1;220(3):e202004211.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA